New drug duo takes aim at Tough-to-Treat colon cancer
Disease control
Recruiting now
This study is for people with advanced colorectal cancer that has spread and has a specific genetic change called BRAF V600E, and whose cancer has worsened after at least one prior treatment. It aims to see if a new combination of two targeted drugs (tunlametinib and vemurafenib)…
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC